Association between metabolic syndrome and 13 types of cancer in Catalonia: A matched case-control study.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
24
09
2021
accepted:
14
02
2022
entrez:
4
3
2022
pubmed:
5
3
2022
medline:
27
4
2022
Statut:
epublish
Résumé
Metabolic syndrome (MS) is the simultaneous occurrence of a cluster of predefined cardiovascular risk factors. Although individual MS components are associated with increased risk of cancer, it is still unclear whether the association between MS and cancer differs from the association between individual MS components and cancer. The aim of this matched case-control study was to estimate the association of 13 types of cancer with (1) MS and (2) the diagnosis of 0, 1 or 2 individual MS components. Cases included 183,248 patients ≥40 years from the SIDIAP database with incident cancer diagnosed between January 2008-December 2017. Each case was matched to four controls by inclusion date, sex and age. Adjusted conditional logistic regression models were used to evaluate the association between MS and cancer risk, comparing the effect of global MS versus having one or two individual components of MS. MS was associated with an increased risk of the following cancers: colorectal (OR: 1.28, 95%CI: 1.23-1.32), liver (OR: 1.93, 95%CI: 1.74-2.14), pancreas (OR: 1.79, 95%CI: 1.63-1.98), post-menopausal breast (OR: 1.10, 95%CI: 1.06-1.15), pre-menopausal endometrial (OR: 2.14, 95%CI: 1.74-2.65), post-menopausal endometrial (OR: 2.46, 95%CI: 2.20-2.74), bladder (OR: 1.41, 95%CI: 1.34-1.48), kidney (OR: 1.84, 95%CI: 1.69-2.00), non-Hodgkin lymphoma (OR: 1.23, 95%CI: 1.10-1.38), leukaemia (OR: 1.42, 95%CI: 1.31-1.54), lung (OR: 1.11, 95%CI: 1.05-1.16) and thyroid (OR: 1.71, 95%CI: 1.50-1.95). Except for prostate, pre-menopause breast cancer and Hodgkin and non-Hodgkin lymphoma, MS is associated with a higher risk of cancer than 1 or 2 individual MS components. Estimates were significantly higher in men than in women for colorectal and lung cancer, and in smokers than in non-smokers for lung cancer. MS is associated with a higher risk of developing 11 types of common cancer, with a positive correlation between number of MS components and risk of cancer.
Sections du résumé
BACKGROUND
Metabolic syndrome (MS) is the simultaneous occurrence of a cluster of predefined cardiovascular risk factors. Although individual MS components are associated with increased risk of cancer, it is still unclear whether the association between MS and cancer differs from the association between individual MS components and cancer. The aim of this matched case-control study was to estimate the association of 13 types of cancer with (1) MS and (2) the diagnosis of 0, 1 or 2 individual MS components.
METHODS
Cases included 183,248 patients ≥40 years from the SIDIAP database with incident cancer diagnosed between January 2008-December 2017. Each case was matched to four controls by inclusion date, sex and age. Adjusted conditional logistic regression models were used to evaluate the association between MS and cancer risk, comparing the effect of global MS versus having one or two individual components of MS.
RESULTS
MS was associated with an increased risk of the following cancers: colorectal (OR: 1.28, 95%CI: 1.23-1.32), liver (OR: 1.93, 95%CI: 1.74-2.14), pancreas (OR: 1.79, 95%CI: 1.63-1.98), post-menopausal breast (OR: 1.10, 95%CI: 1.06-1.15), pre-menopausal endometrial (OR: 2.14, 95%CI: 1.74-2.65), post-menopausal endometrial (OR: 2.46, 95%CI: 2.20-2.74), bladder (OR: 1.41, 95%CI: 1.34-1.48), kidney (OR: 1.84, 95%CI: 1.69-2.00), non-Hodgkin lymphoma (OR: 1.23, 95%CI: 1.10-1.38), leukaemia (OR: 1.42, 95%CI: 1.31-1.54), lung (OR: 1.11, 95%CI: 1.05-1.16) and thyroid (OR: 1.71, 95%CI: 1.50-1.95). Except for prostate, pre-menopause breast cancer and Hodgkin and non-Hodgkin lymphoma, MS is associated with a higher risk of cancer than 1 or 2 individual MS components. Estimates were significantly higher in men than in women for colorectal and lung cancer, and in smokers than in non-smokers for lung cancer.
CONCLUSION
MS is associated with a higher risk of developing 11 types of common cancer, with a positive correlation between number of MS components and risk of cancer.
Identifiants
pubmed: 35245317
doi: 10.1371/journal.pone.0264634
pii: PONE-D-21-30858
pmc: PMC8896701
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0264634Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
BMC Cancer. 2015 Oct 16;15:720
pubmed: 26475132
Metabolism. 2011 Oct;60(10):1372-8
pubmed: 21550085
Med Oncol. 2015 Jan;32(1):422
pubmed: 25471791
JAMA. 2002 Jan 16;287(3):356-9
pubmed: 11790215
Diabetes Care. 2012 Nov;35(11):2402-11
pubmed: 23093685
Lancet. 2008 Feb 16;371(9612):569-78
pubmed: 18280327
Nutr Metab (Lond). 2017 Feb 28;14:21
pubmed: 28261315
Med Clin (Barc). 2012 May 19;138(14):617-21
pubmed: 22444996
Ann Oncol. 2010 May;21 Suppl 3:iii3-13
pubmed: 20427357
J Clin Endocrinol Metab. 2020 Nov 1;105(11):
pubmed: 32860708
Clin Epidemiol. 2019 Dec 03;11:1015-1024
pubmed: 31819655
Diabet Med. 2006 May;23(5):469-80
pubmed: 16681555
BMJ Open. 2019 Jun 14;9(6):e025365
pubmed: 31201184
Diabetol Metab Syndr. 2019 Oct 10;11:83
pubmed: 31624504
Front Endocrinol (Lausanne). 2020 Jan 21;10:905
pubmed: 32038481
Stat Med. 2011 Feb 20;30(4):377-99
pubmed: 21225900
J Investig Med. 2018 Jan;66(1):22-31
pubmed: 28866631
Menopause. 2013 Dec;20(12):1301-9
pubmed: 23571527
Cell Signal. 2012 Aug;24(8):1515-21
pubmed: 22481093
J Clin Epidemiol. 2019 Jun;110:63-73
pubmed: 30878639
Am J Epidemiol. 2010 Mar 1;171(5):624-32
pubmed: 20106935
Cancer Causes Control. 2011 May;22(5):743-51
pubmed: 21380729
Circulation. 2009 Oct 20;120(16):1640-5
pubmed: 19805654
Cancer Epidemiol Biomarkers Prev. 2019 Dec;28(12):2038-2046
pubmed: 31533942
Int J Cancer. 2021 Feb 15;148(4):825-834
pubmed: 33405276
J Cell Mol Med. 2019 Feb;23(2):934-942
pubmed: 30450757
Diabetol Metab Syndr. 2020 Oct 28;12:95
pubmed: 33133241
Rev Esp Cardiol (Engl Ed). 2014 May;67(5):367-73
pubmed: 24774729
BMC Public Health. 2015 Sep 18;15:913
pubmed: 26385727
Nat Rev Urol. 2018 May;15(5):321-333
pubmed: 29434372
Rev Esp Cardiol (Engl Ed). 2012 Mar;65(3):241-8
pubmed: 22305818
Anticancer Res. 2015 Apr;35(4):2211-4
pubmed: 25862880
Circulation. 2004 Jan 27;109(3):433-8
pubmed: 14744958
Int J Cancer. 2020 Dec 15;147(12):3384-3393
pubmed: 32580250
Aging (Albany NY). 2020 May 22;12(10):9825-9839
pubmed: 32439832
Am J Epidemiol. 1999 Jan 15;149(2):195-7
pubmed: 9921965
Cancer Manag Res. 2018 Nov 26;10:6263-6274
pubmed: 30568489
Acta Diabetol. 2010 Jun;47(2):87-95
pubmed: 20376506
Cancer Epidemiol Biomarkers Prev. 2020 Oct;29(10):2038-2047
pubmed: 32763912
J Clin Med. 2019 Aug 28;8(9):
pubmed: 31466366
Gut. 2021 Jun;70(6):1147-1154
pubmed: 33037055
Thyroid. 2020 Oct;30(10):1496-1504
pubmed: 32524894